Core Insights - Clene Inc. announced new preclinical data indicating that CNM-Au8® improves cellular health in a dopaminergic neuron model of Parkinson's disease, showcasing its potential therapeutic benefits [1][4][6] Group 1: Study Details - The study utilized skin cells from 8 sporadic PD patients, 14 familial PD patients, and 13 healthy individuals, converting them into dopaminergic neurons to study disease processes [2] - The innovative model retains age-related characteristics, allowing for a more accurate representation of Parkinson's disease [2] Group 2: Key Findings - CNM-Au8 treatment improved mitochondrial health, restored cellular metabolism, reduced inflammation, and normalized dysregulated gene expression in both familial and sporadic Parkinson's disease [4][5] - Specifically, CNM-Au8 increased mitochondrial health and volume while reducing harmful reactive oxygen species in familial PD neurons, with milder effects in sporadic PD neurons [5] - The treatment also lowered levels of inflammatory proteins in sporadic PD neurons, contributing to reduced neuroinflammation [5] - CNM-Au8 increased the NAD+/NADH ratio, correcting intracellular metabolite levels in both familial and sporadic PD neurons [5] - The treatment normalized gene expression profiles in PD neurons, bringing them closer to control levels [5] Group 3: Safety and Future Development - CNM-Au8 demonstrated a favorable safety profile, showing no toxicity towards dopaminergic cells at all tested doses, consistent with clinical observations from previous studies [5] - Clene is advancing CNM-Au8 through late-stage clinical studies for ALS and plans to design a Phase 2 clinical study for Parkinson's disease [6]

Core Insights - Clene Inc. and its subsidiary Clene Nanomedicine Inc. are focused on revolutionizing treatments for neurodegenerative diseases such as ALS and MS [1][2] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference and host 1x1 investor meetings [1] Company Overview - Clene Inc. is a late clinical-stage biopharmaceutical company dedicated to improving mitochondrial health and protecting neuronal function [2] - The investigational therapy CNM-Au8 targets mitochondrial function and the NAD pathway, aiming to enhance the survival and function of central nervous system cells while reducing oxidative stress [2] - Clene is headquartered in Salt Lake City, Utah, with R&D and manufacturing operations located in Maryland [2]

About Clene Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mec ...